We continue to monitor the pharmaceutical regulatory sector as well as the medical literature for developments as regards the increased risks of cancers, blood clots, heart problems, and deaths associated with Xeljanz, Olumiant, and Rinvoq.
In December 2021 there was another JAK inhibitors drug class safety development, with Xeljanz, Olumiant, and Rinvoq getting revised drug labels with more side effects warnings and more drug use restrictions. These December 2021 label changes were “new” but anticipated because back in September 2021 the FDA announced that it was requiring revisions to the “Black-Box” warnings already on the drug labels for Xeljanz, Olumiant, and Rinvoq “to include more information about the risks of serious heart-related events, cancer, blood clots, and death.”
Xeljanz is a Pfizer drug, Rinvoq is an AbbVie drug, and Olumiant is an Eli Lilly drug. The pharmaceutical companies AbbieVie and Eli Lilly have attempted to distinguish the safety profile of their respective JAK inhibitors drug product from the various adverse drug reactions that have been observed in the Xeljanz clinical trial that have driven the FDA regulatory actions driving these December drug label changes.
One pharmaceutical industry commentator wrote after the latest Xeljanz, Olumiant, and Rinvoq label changes said he thinks that AbbVie may have an advantage in “market share” going forward as regards the three JAK inhibitors drugs approved for the treatment of rheumatoid arthritis, given some details of the new drug label for Rinvoq.
Our law firm is investigating possible Xeljanz, Olumiant, and Rinvoq lawsuits for patients who have suffered serious side effects or adverse drug reactions while using one of these JAK inhibitors. In particular, we are reviewing cases of cancers, blood clots, heart problems, and deaths associated with Xeljanz, Olumiant, and Rinvoq.
If we can be of assistance to you or someone you know, please feel free to contact us, at your convenience.[Read article in full at original source]
Strictly Confidential, No Obligation